NO864518L - Fremgangsmaate for fremstilling av thiazolo(4,5-c)kinoliner - Google Patents

Fremgangsmaate for fremstilling av thiazolo(4,5-c)kinoliner

Info

Publication number: NO864518L
Authority: NO; Norway
Prior art keywords: general formula; quinoline; thiazolo; acid addition; acid
Prior art date: 1985-11-12

Application number

NO864518A

Other languages

English (en)

Norwegian (no)

Other versions

NO864518D0 (no

Inventor

Jozsef Knoll

Edit Berenyi

Katalin Budai

Berta Knoll

Zsuzsa Fuerts

Julia Timbr

Gabriella Zsila

Ildiko Niklya

Lujza Petoz

Attila Mandi

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-11-12

Filing date

1986-11-12

Publication date

1987-05-13

1986-11-12 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

1986-11-12 Publication of NO864518D0 publication Critical patent/NO864518D0/no

1987-05-13 Publication of NO864518L publication Critical patent/NO864518L/no

Links

238000000034 method Methods 0.000 title claims description 27
238000002360 preparation method Methods 0.000 title claims description 4
229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
150000003248 quinolines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 36
239000002253 acid Substances 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
238000006243 chemical reaction Methods 0.000 claims description 16
239000011541 reaction mixture Substances 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
YJBLTYRYUXKJLE-UHFFFAOYSA-N 3-amino-1h-quinoline-4-thione Chemical compound C1=CC=C2C(=S)C(N)=CNC2=C1 YJBLTYRYUXKJLE-UHFFFAOYSA-N 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 11
OWHMGQJEHHCWCJ-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]quinoline Chemical class C1=CC=CC2=C(SC=N3)C3=CN=C21 OWHMGQJEHHCWCJ-UHFFFAOYSA-N 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 6
239000007858 starting material Substances 0.000 claims description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
150000008064 anhydrides Chemical class 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 3
239000007800 oxidant agent Substances 0.000 claims description 3
125000004950 trifluoroalkyl group Chemical group 0.000 claims description 3
150000004820 halides Chemical class 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
238000012360 testing method Methods 0.000 description 22
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
230000011514 reflex Effects 0.000 description 15
239000000203 mixture Substances 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
239000000243 solution Substances 0.000 description 12
230000001143 conditioned effect Effects 0.000 description 10
238000007920 subcutaneous administration Methods 0.000 description 10
241000700159 Rattus Species 0.000 description 9
230000000694 effects Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
PTPFCOYIENEVQA-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]quinoline;hydrochloride Chemical compound Cl.C1=CC=CC2=C(SC=N3)C3=CN=C21 PTPFCOYIENEVQA-UHFFFAOYSA-N 0.000 description 6
OSUDJKDDCBAIBJ-UHFFFAOYSA-N ethanesulfonic acid;[1,3]thiazolo[4,5-c]quinoline Chemical compound CCS(O)(=O)=O.C1=CC=CC2=C(SC=N3)C3=CN=C21 OSUDJKDDCBAIBJ-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000009835 boiling Methods 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000012429 reaction media Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
238000000540 analysis of variance Methods 0.000 description 4
229940049706 benzodiazepine Drugs 0.000 description 4
229960003529 diazepam Drugs 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
-1 hydroxy, nitro, amino Chemical group 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000009191 jumping Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
230000036407 pain Effects 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
229920000137 polyphosphoric acid Polymers 0.000 description 4
238000003756 stirring Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000013016 learning Effects 0.000 description 3
239000000155 melt Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
230000004899 motility Effects 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003874 central nervous system depressant Substances 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
229960004782 chlordiazepoxide Drugs 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000008058 pain sensation Effects 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
230000004622 sleep time Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000012549 training Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000008096 xylene Substances 0.000 description 2
FYWDUUCSIVYZLY-UHFFFAOYSA-N 2-(trifluoromethyl)-[1,3]thiazolo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(SC(C(F)(F)F)=N3)C3=CN=C21 FYWDUUCSIVYZLY-UHFFFAOYSA-N 0.000 description 1
SINZPEYYUQJQBM-UHFFFAOYSA-N 2-ethyl-[1,3]thiazolo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(SC(CC)=N3)C3=CN=C21 SINZPEYYUQJQBM-UHFFFAOYSA-N 0.000 description 1
WJDUOAAAWXDSHV-UHFFFAOYSA-N 2-methyl-[1,3]thiazolo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(SC(C)=N3)C3=CN=C21 WJDUOAAAWXDSHV-UHFFFAOYSA-N 0.000 description 1
LHGQMWURUMTIIZ-UHFFFAOYSA-N 2-phenyl-[1,3]thiazolo[4,5-c]quinoline Chemical compound C1=CC=CC=C1C1=NC2=CN=C(C=CC=C3)C3=C2S1 LHGQMWURUMTIIZ-UHFFFAOYSA-N 0.000 description 1
DYNFNQSYNRGKMY-UHFFFAOYSA-N 3-amino-1h-quinoline-4-thione;hydrochloride Chemical compound Cl.C1=CC=CC2=C(S)C(N)=CN=C21 DYNFNQSYNRGKMY-UHFFFAOYSA-N 0.000 description 1
HPCLSFSEORFCOS-UHFFFAOYSA-N 3-amino-7-chloro-1h-quinoline-4-thione Chemical compound C1=C(Cl)C=CC2=C(S)C(N)=CN=C21 HPCLSFSEORFCOS-UHFFFAOYSA-N 0.000 description 1
HMHBYAPCFAFYMH-UHFFFAOYSA-N 7-chloro-2-methyl-[1,3]thiazolo[4,5-c]quinoline Chemical compound C1=C(Cl)C=CC2=C(SC(C)=N3)C3=CN=C21 HMHBYAPCFAFYMH-UHFFFAOYSA-N 0.000 description 1
LGCDESMZDJRZHB-UHFFFAOYSA-N 7-chloro-[1,3]thiazolo[4,5-c]quinoline Chemical compound C1=NC2=CC(Cl)=CC=C2C2=C1N=CS2 LGCDESMZDJRZHB-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000004300 GABA-A Receptors Human genes 0.000 description 1
108090000839 GABA-A Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
CEWCKUSQGANLCP-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]isoquinoline Chemical class C1=CC=CC2=C(SC=N3)C3=NC=C21 CEWCKUSQGANLCP-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000026781 habituation Effects 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
KSHSRFOLLXJJGF-UHFFFAOYSA-N n-(7-chloro-4-sulfanylidene-1h-quinolin-3-yl)acetamide Chemical compound C1=C(Cl)C=CC2=C(S)C(NC(=O)C)=CN=C21 KSHSRFOLLXJJGF-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
208000018299 prostration Diseases 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO864518A 1985-11-12 1986-11-12 Fremgangsmaate for fremstilling av thiazolo(4,5-c)kinoliner NO864518L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU854304A HU197019B (en)	1985-11-12	1985-11-12	Process for producing thiqzolo (4,5-c) quinoline derivatives and pharmaceuticals comprising same

Publications (2)

Publication Number	Publication Date
NO864518D0 NO864518D0 (no)	1986-11-12
NO864518L true NO864518L (no)	1987-05-13

Family

ID=10967593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO864518A NO864518L (no)	1985-11-12	1986-11-12	Fremgangsmaate for fremstilling av thiazolo(4,5-c)kinoliner

Country Status (24)

Country	Link
US (1)	US4904669A (de)
JP (1)	JPS62161792A (de)
CN (1)	CN86107754A (de)
AU (1)	AU592384B2 (de)
BE (1)	BE905719A (de)
BG (1)	BG46156A3 (de)
CH (1)	CH670829A5 (de)
DD (1)	DD254202A5 (de)
DE (1)	DE3638563A1 (de)
DK (1)	DK539786A (de)
ES (1)	ES2002543A6 (de)
FI (1)	FI864611A7 (de)
FR (1)	FR2603588A1 (de)
GB (1)	GB2184117B (de)
HU (1)	HU197019B (de)
IL (1)	IL80611A0 (de)
IT (1)	IT1213379B (de)
NL (1)	NL8602878A (de)
NO (1)	NO864518L (de)
PL (1)	PL148186B1 (de)
SE (1)	SE8604839L (de)
SU (1)	SU1544190A3 (de)
YU (1)	YU192186A (de)
ZA (1)	ZA868583B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU199423B (en) *	1987-04-24	1990-02-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing 3-amino-4-/ethylthio/-quinoline and pharmaceutical compositions comprising such compounds
US6110929A (en)	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
WO2004096144A2 (en) *	2003-04-28	2004-11-11	3M Innovative Properties Company	Compositions and methods for induction of opioid receptors
BRPI0413558A (pt) *	2003-08-12	2006-10-17	3M Innovative Properties Co	compostos contendo imidazo substituìdo por hidroxilamina
AU2004268625B2 (en) *	2003-08-27	2011-03-31	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
AR046046A1 (es) *	2003-10-03	2005-11-23	3M Innovative Properties Co	Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
EP1685129A4 (de)	2003-11-14	2008-10-22	3M Innovative Properties Co	Oximsubstituierte imidazoringverbindungen
CA2545825A1 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) *	2003-11-25	2014-03-25	3M Innovative Properties Company	1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
JP2007517035A (ja) *	2003-12-29	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (de) *	2003-12-30	2006-09-13	3M Innovative Properties Company	Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
WO2005094531A2 (en) *	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) *	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) *	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
WO2006065280A2 (en) *	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) *	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
EP1819364A4 (de) *	2004-12-08	2010-12-29	3M Innovative Properties Co	Immunmodulatorische zusammensetzungen, kombinationen und verfahren
JP5543068B2 (ja) *	2004-12-30	2014-07-09	スリーエムイノベイティブプロパティズカンパニー	キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1831221B1 (de)	2004-12-30	2012-08-08	3M Innovative Properties Company	Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen
AU2006210392A1 (en) *	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
US8378102B2 (en) *	2005-02-09	2013-02-19	3M Innovative Properties Company	Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
AU2006213746A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
EP1869043A2 (de)	2005-04-01	2007-12-26	Coley Pharmaceutical Group, Inc.	Pyrazolopyridin-1,4-diamine und analoge davon
AU2006232375A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7906506B2 (en) *	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2020083662A1 (en)	2018-10-23	2020-04-30	Basf Se	Tricyclic pesticidal compounds
EP4136086A1 (de)	2020-04-14	2023-02-22	Basf Se	Tricyclische pestizidverbindungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2024207A (en) *	1978-05-26	1980-01-09	Lepetit Spa	New tricyclic ortho-fused heterocyclic compounds
HU196308B (en) *	1985-11-12	1988-11-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing pharmaceutical compositions containing 2-methyl-thiazolo/4,5-c/quinoline as active component

1985
- 1985-11-12 HU HU854304A patent/HU197019B/hu not_active IP Right Cessation
1986
- 1986-11-07 BE BE1/011572A patent/BE905719A/fr not_active IP Right Cessation
- 1986-11-10 CH CH4491/86A patent/CH670829A5/de not_active IP Right Cessation
- 1986-11-12 SU SU864028529A patent/SU1544190A3/ru active
- 1986-11-12 IL IL80611A patent/IL80611A0/xx unknown
- 1986-11-12 ES ES8603003A patent/ES2002543A6/es not_active Expired
- 1986-11-12 IT IT8622312A patent/IT1213379B/it active
- 1986-11-12 BG BG77078A patent/BG46156A3/xx unknown
- 1986-11-12 PL PL1986262346A patent/PL148186B1/pl unknown
- 1986-11-12 ZA ZA868583A patent/ZA868583B/xx unknown
- 1986-11-12 US US06/929,353 patent/US4904669A/en not_active Expired - Fee Related
- 1986-11-12 NL NL8602878A patent/NL8602878A/nl not_active Application Discontinuation
- 1986-11-12 SE SE8604839A patent/SE8604839L/xx not_active Application Discontinuation
- 1986-11-12 JP JP61267869A patent/JPS62161792A/ja active Pending
- 1986-11-12 FR FR8615655A patent/FR2603588A1/fr active Pending
- 1986-11-12 DK DK539786A patent/DK539786A/da not_active Application Discontinuation
- 1986-11-12 FI FI864611A patent/FI864611A7/fi not_active Application Discontinuation
- 1986-11-12 NO NO864518A patent/NO864518L/no unknown
- 1986-11-12 GB GB8627043A patent/GB2184117B/en not_active Expired
- 1986-11-12 DE DE19863638563 patent/DE3638563A1/de not_active Withdrawn
- 1986-11-12 YU YU01921/86A patent/YU192186A/xx unknown
- 1986-11-12 DD DD86296208A patent/DD254202A5/de not_active IP Right Cessation
- 1986-11-12 CN CN198686107754A patent/CN86107754A/zh active Pending
- 1986-11-12 AU AU65089/86A patent/AU592384B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SU1544190A3 (ru)	1990-02-15
DK539786D0 (da)	1986-11-12
IL80611A0 (en)	1987-02-27
YU192186A (en)	1988-10-31
DK539786A (da)	1987-05-13
PL262346A1 (en)	1988-03-03
AU592384B2 (en)	1990-01-11
JPS62161792A (ja)	1987-07-17
BE905719A (fr)	1987-05-07
HU197019B (en)	1989-02-28
GB2184117B (en)	1989-10-11
US4904669A (en)	1990-02-27
GB8627043D0 (en)	1986-12-10
FI864611A0 (fi)	1986-11-12
ES2002543A6 (es)	1988-08-16
CH670829A5 (de)	1989-07-14
DD254202A5 (de)	1988-02-17
CN86107754A (zh)	1987-08-05
BG46156A3 (en)	1989-10-16
PL148186B1 (en)	1989-09-30
FR2603588A1 (fr)	1988-03-11
IT8622312A0 (it)	1986-11-12
AU6508986A (en)	1987-05-14
SE8604839D0 (sv)	1986-11-12
NO864518D0 (no)	1986-11-12
GB2184117A (en)	1987-06-17
IT1213379B (it)	1989-12-20
SE8604839L (sv)	1987-05-13
HUT44260A (en)	1988-02-29
ZA868583B (en)	1987-08-26
NL8602878A (nl)	1987-06-01
DE3638563A1 (de)	1987-06-25
FI864611A7 (fi)	1987-05-13

Publication	Publication Date	Title
NO864518L (no)	1987-05-13	Fremgangsmaate for fremstilling av thiazolo(4,5-c)kinoliner
KR900006853B1 (ko)	1990-09-22	약리학적으로 활성인 피라졸로/4,3-c/피리딘의 제조방법
KR101383228B1 (ko)	2014-04-09	Ａ3 아데노신 수용체 알로스테릭 조절제
SK280822B6 (sk)	2000-08-14	Imidazopyridíny, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie
NZ264887A (en)	1996-12-20	Heterocyclic carboxamides
EP2119704A1 (de)	2009-11-18	Acylguanidinderivat
SK283536B6 (sk)	2003-09-11	Pyridylftalazindióny, spôsob ich prípravy a použitie a farmaceutické prostriedky na ich báze
KR910006986B1 (ko)	1991-09-14	치환된 5,11-디하이드로-6H-디벤즈[b,e]아제핀-6-온의 제조방법
CN115925699B (zh)	2023-10-03	具有镇痛活性的稠环化合物及其制备方法与用途
US20130005709A1 (en)	2013-01-03	Sulfone compounds as 5-ht6 receptor ligands
HU182562B (en)	1984-02-28	Process for preparing new 4-amino-2-piperidino-quinazoline derivatives
AU623205B2 (en)	1992-05-07	N-pyridinyl-9h-carbazol-9-amines, a process their preparation and their use as medicaments
US4778811A (en)	1988-10-18	Pharmaceutical compositions of 2-methyl-thiazolo[4,5-c]quinoline
KR100557804B1 (ko)	2006-06-20	인돌로모르피난유도체및뇌장해치료·예방제
HU220874B1 (en)	2002-06-29	Imidazopyridine-azolidinones, process for producing them, the use thereof and pharmaceutical compositions containing them
DK149753B (da)	1986-09-22	Analogifremgangsmaade til fremstilling af morfinderivater
BR112019016775A2 (pt)	2020-03-31	Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
SK8732000A3 (en)	2000-11-07	Potassium channel openers
US4350698A (en)	1982-09-21	Antiallergic imidosulfamides
Cingolani et al.	1988	Indolizine derivatives with biological activity V. 1-(2-Aminoethyl)-2-methylindolizine and its N-alkyl derivatives
PL94080B1 (en)	1977-07-30	Lactams and process for their manufacture[US3951985A]
AU602209B2 (en)	1990-10-04	Quinoline thioethers
RU2780531C1 (ru)	2022-09-26	N-замещенные 4-(1-гидрокси-1-метил-2-аминоэтил)бензойные кислоты, обладающие анксиолитической активностью, их фармацевтически приемлемые соли и способ их получения
JP2003513006A (ja)	2003-04-08	三環性鎮痛薬
US4996223A (en)	1991-02-26	New organic compounds having opioid properties